Aligos Therapeutics, Inc.
NASDAQ:ALGS
5.94 (USD) • At close May 13, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2025 Q1 | 2024 Q4 | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | 2022 Q2 | 2022 Q1 | 2021 Q4 | 2021 Q3 | 2021 Q2 | 2021 Q1 | 2020 Q4 | 2020 Q3 | 2020 Q2 | 2020 Q1 | 2019 Q4 | 2019 Q3 | 2019 Q2 | 2019 Q1 | 2018 Q2 | 2018 Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0.311 | 0.629 | 1.269 | 1.061 | 0.986 | 2.681 | 3.239 | 6.886 | 2.723 | 3.537 | 4.106 | 3.693 | 2.571 | 0.367 | 1.537 | 1.545 | 0.91 | 0 | 2.026 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0 | 0 | 0 | 0.61 | 0.674 | 0.775 | 0.681 | 0.769 | 0.844 | 0.897 | 0.906 | 0.889 | 0.983 | 28.598 | 28.132 | 24.554 | 22.869 | 28.081 | 17.332 | 17.176 | 17.302 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit
| 0.311 | -0.042 | 1.269 | 0.451 | 0.312 | 1.906 | 2.558 | 6.117 | 1.879 | 2.64 | 3.2 | 2.804 | 1.588 | -28.231 | -26.595 | -23.009 | -21.959 | -28.081 | -15.306 | -17.176 | -17.302 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit Ratio
| 1 | -0.067 | 1 | 0.425 | 0.316 | 0.711 | 0.79 | 0.888 | 0.69 | 0.746 | 0.779 | 0.759 | 0.618 | -76.924 | -17.303 | -14.893 | -24.131 | 0 | -7.555 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 14.502 | 16.03 | 16.774 | 21.099 | 16.366 | 22.257 | 15.867 | 16.781 | 18.135 | 19.1 | 17.791 | 16.51 | 31.676 | 28.598 | 28.132 | 24.554 | 22.869 | 28.081 | 17.332 | 17.176 | 17.302 | 14.973 | 11.729 | 8.668 | 8.668 | 2.614 | 2.614 |
| General & Administrative Expenses
| 5.052 | 5.161 | 4.626 | 6.376 | 6.666 | 6.421 | 6.443 | 9.246 | 8.506 | 7.119 | 5.263 | 7.576 | 6.452 | 9.717 | 6.473 | 6.556 | 5.781 | 6.205 | 4.225 | 4.095 | 3.419 | 3.463 | 2.775 | 1.884 | 1.884 | 0.801 | 0.801 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | -0.61 | 0 | -0.775 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 5.052 | 5.161 | 4.626 | 5.766 | 6.666 | 5.646 | 6.443 | 9.246 | 8.506 | 7.119 | 5.263 | 7.576 | 6.452 | 9.717 | 6.473 | 6.556 | 5.781 | 6.205 | 4.225 | 4.095 | 3.419 | 3.463 | 2.775 | 1.884 | 1.884 | 0.801 | 0.801 |
| Other Expenses
| 0 | 0 | 0 | 31.345 | -13.373 | -0.46 | 0.054 | 0.152 | 0.254 | 0 | -0.182 | 0.304 | -0.091 | 0 | 0.05 | -0.298 | 0.006 | 1.07 | -11.974 | 0.041 | 0.224 | 0.083 | 0.108 | 0 | 0 | -6.831 | -6.831 |
| Operating Expenses
| 19.554 | 21.192 | 21.4 | 26.865 | 23.032 | 27.903 | 22.31 | 26.027 | 26.641 | 26.219 | 23.054 | 24.086 | 38.128 | 38.315 | 34.605 | 31.11 | 28.65 | 34.286 | 21.557 | 21.271 | 20.721 | 18.436 | 14.504 | 10.497 | 10.497 | -3.415 | -3.415 |
| Operating Income
| -19.243 | -20.563 | -20.131 | -26.414 | -22.046 | -25.997 | -19.071 | -19.141 | -21.914 | -22.682 | -18.948 | -20.393 | -35.557 | -37.948 | -33.068 | -29.565 | -27.74 | -34.286 | -21.557 | -21.271 | -20.721 | -18.436 | -14.504 | -10.552 | -10.552 | -3.415 | -3.415 |
| Operating Income Ratio
| -61.875 | -32.692 | -15.864 | -24.895 | -22.359 | -9.697 | -5.888 | -2.78 | -8.048 | -6.413 | -4.615 | -5.522 | -13.83 | -103.401 | -21.515 | -19.136 | -30.484 | 0 | -10.64 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 62.374 | -61.56 | 0.963 | 31.664 | -12.793 | -1.925 | 1.059 | 1.107 | 1.002 | 0.845 | 0.284 | 0.516 | -0.005 | 0.176 | 0.07 | -0.225 | 0.111 | 0.085 | -11.74 | 0.415 | 0.692 | 0.337 | 0.453 | 0.537 | 0.537 | -0.068 | -0.068 |
| Income Before Tax
| 43.131 | -82.123 | -19.168 | 5.25 | -34.839 | -27.922 | -18.012 | -18.034 | -22.916 | -21.837 | -18.664 | -19.877 | -35.562 | -37.772 | -32.998 | -29.79 | -27.629 | -34.201 | -33.297 | -20.856 | -20.029 | -18.099 | -14.051 | -10.015 | -10.015 | -3.483 | -3.483 |
| Income Before Tax Ratio
| 138.685 | -130.561 | -15.105 | 4.948 | -35.334 | -10.415 | -5.561 | -2.619 | -8.416 | -6.174 | -4.546 | -5.382 | -13.832 | -102.921 | -21.469 | -19.282 | -30.362 | 0 | -16.435 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0.043 | 0.027 | 0.091 | 0.189 | -0.024 | -0.03 | 0.029 | 0.757 | 0.039 | 0.049 | -0.043 | 0.047 | 0.053 | -0.058 | 0.126 | 0.028 | 0.045 | 0.219 | -0.234 | -0.059 | -0.468 | 0.085 | -0.345 | 0 | 0 | -0.068 | -0.068 |
| Net Income
| 43.088 | -82.15 | -19.259 | 5.061 | -34.863 | -27.892 | -18.041 | -18.791 | -22.955 | -21.886 | -18.621 | -19.924 | -35.615 | -37.714 | -33.124 | -29.818 | -27.674 | -34.42 | -33.297 | -20.797 | -20.029 | -18.184 | -14.051 | -10.015 | -10.015 | -3.483 | -3.483 |
| Net Income Ratio
| 138.547 | -130.604 | -15.177 | 4.77 | -35.358 | -10.404 | -5.57 | -2.729 | -8.43 | -6.188 | -4.535 | -5.395 | -13.853 | -102.763 | -21.551 | -19.3 | -30.411 | 0 | -16.435 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS
| 5.12 | -13.08 | -3.07 | 0.81 | -5.58 | -1.12 | -0.41 | -0.43 | -0.53 | -0.51 | -0.44 | -0.47 | -0.84 | -0.89 | -0.78 | -0.79 | -0.74 | -1.09 | -0.9 | -0.95 | -0.91 | -0.83 | -0.64 | -0.46 | -0.46 | -0.16 | -0.16 |
| EPS Diluted
| -2.11 | -13.08 | -3.07 | 0.81 | -5.58 | -1.12 | -0.41 | -0.43 | -0.53 | -0.51 | -0.44 | -0.47 | -0.84 | -0.89 | -0.78 | -0.79 | -0.74 | -1.09 | -0.9 | -0.95 | -0.91 | -0.83 | -0.64 | -0.46 | -0.46 | -0.16 | -0.16 |
| EBITDA
| -18.733 | -19.892 | -19.464 | -26.414 | -21.372 | -27.147 | -18.39 | -18.372 | -23.074 | -22.16 | -17.758 | -19.504 | -34.579 | -37.948 | -32.031 | -28.865 | -26.756 | -33.318 | -20.842 | -20.312 | -20.261 | -17.792 | -13.878 | -10.311 | -10.311 | -3.161 | -3.161 |
| EBITDA Ratio
| -60.235 | -31.625 | -15.338 | -24.895 | -21.675 | -10.126 | -5.678 | -2.668 | -8.474 | -6.265 | -4.325 | -5.281 | -13.45 | -103.401 | -20.84 | -18.683 | -29.402 | 0 | -10.287 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |